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1. Introduction 
Close to one century ago, Joslin, an American diabetologist, proposed the link between 
diabetes and obesity [1]. He concluded that “diabetes is largely a penalty of obesity, and the 
greater the obesity, the more likely is Nature to enforce it”. In the 1950s, Vague [2] described 
that central obesity predisposes not only to diabetes but also to atherosclerosis. In the 1970s, 
for the first time, Haller [3] used the term "metabolic syndrome" (MetS) for associations of 
obesity, diabetes mellitus (DM), hyperlipoproteinemia, hyperuricemia, and hepatic steatosis 
when describing the additive effects of risk factors on atherosclerosis. Phillips developed the 
concept of metabolic risk factors for myocardial infarction and described a cluster of 
abnormalities including glucose intolerance, hyperinsulinemia, hyperlipidemia, and 
hypertension [4,5]. In 1988, Reaven, an American endocrinologist, propounded that insulin 
resistance (IR) was the cause of glucose intolerance, hyperinsulinaemia, increased very-low-
density lipoprotein cholesterol (VLDL-C), decreased high-density lipoprotein cholesterol 
(HDL-C) and hypertension and named the constellation of abnormalities “syndrome X” [6]. 
Reaven did not include abdominal obesity, which has also been hypothesized as the 
underlying factor, as part of the condition. In the late 1990s and the early 21st century, MetS 
was widely recognized as a leading risk factor for cardiovascular morbidity and mortality 
and variously defined by World Health Organization [7], International Diabetes Federation 
(IDF [8]), the European Group for the Study of Insulin Resistance [9] and the National 
Cholesterol Education Program Adult Treatment Panel III [10] based on the reference 
intervals of its components. Accordingly to these definitions, MetS is thought to represent a 
combination of cardiometabolic risk determinants, including obesity, glucose intolerance 
and IR, dyslipidemia (including hypertriglyceridaemia, increased free fatty acids (FFAs) and 
decreased HDL-C) and hypertension and more recently a growing list of clinical 
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manifestations like polycystic ovarian syndrome (PCOS), atherosclerosis, proinflammatory 
state, oxidative stress and non-alcoholic fatty liver disease (NAFLD) has been associated to 
it. 
The MetS is increasingly recognized as a strong predictor of patient risk for developing 
coronary artery disease. It is associated with an atherogenic dyslipidemia characterized by 
elevated levels of triglycerides (TGs), reduced levels of HDL-C and a preponderance of 
small dense low-density lipoprotein (LDL) particles [11]. An atherogenic dyslipidemia is an 
integral component of MetS, and a major contributor to the cardiovascular risks in patients. 
These alarming situations increase the priority for developing new methods and 
technologies to investigate and to fight the MetS and its related comorbidities. Translational 
physiology offers us specific animal models for investigating these conditions to help 
support biomedical research efforts towards finding the necessary cures. This chapter 
summarizes various types of animal models that used as a tool in lipoprotein clinical 
researches and critically evaluates the physiological fidelity of these animal models to the 
human condition. The animal models are used to investigate biological or pathobiological 
phenomena or employed to find therapeutic and/or toxic effects of a xenobiotic or food 
ingredients. The laboratory animal models are developed and used to study the cause, 
nature, and cure of human lipoprotein disorders. They may conveniently be categorized in 
one of the following two groups:  
1. Experimental animal models of lipoprotein disorders 
2. Spontaneous animal models of lipoprotein disorders 
2. Experimental animal models of lipoprotein disorders 
Experimental (induced) models are healthy animals in which the condition (usually disease) 
to be investigated is experimentally induced, for instance, the induction of DM with 
encephalomyocarditis virus or alloxan. Although homologous animal models that 
completely show symptoms and the course of the lipoprotein metabolic disorders are very 
rare, the most induced models are exploratory, helping to understand mechanisms 
operative in fundamental normal biology or mechanisms associated with an abnormal 
biological function. Generally, induced models of metabolic disorders are prepared by 
genetic manipulation, dietary intervention, surgery, applying xenobiotics (drugs or toxins), 
and a combination of mentioned methods (see review [12]). This chapter will focus mainly 
on diet-induced and spontaneous animal models commonly used to investigate lipoprotein 
metabolic disorders. Readers referred to chapter 22 to study transgenic models of 
lipoprotein disorders. 
Nowadays, obesity, particularly visceral (or central) obesity, is accepted as network 
backbone of the other MetS components and their manifestations. It has been reported that 
the incidence of MetS and type 2 diabetes (T2D) increases with the severity of obesity [13]. 
In this context, increasing body mass index is positively associated with prevalence of both 
impaired glucose tolerance and T2D and also correlated with dyslipidemia component of 
MetS that characterized by (a) increased flux of free fatty acids (FFA), (b) raised TGs values, 
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(c) low HDL-C values, (d) increased small, dense low density lipoprotein particles (e) 
increased TC and LDL-C and (f) raised apolipoprotein (apo) B levels  
The intake of high energy diet and sedentary behavior in developed countries has an accrual 
effect on the incidence of obesity. Although the association between visceral fat and MetS is 
strong, the mechanism is not fully elucidated. The adipose tissue is not an inert tissue and 
constitutively produces adipocytokines that involve in pathogenesis of MetS and IR (see 
review [14]). Diets play a fundamental role in inducing obesity-related diseases in human, 
and most animal models do use diet as a way to precipitate the obesity-related diseases. 
Today, most diet-driven animal disease models are generated using open source, purified 
ingredient diets. The “open source” nature of purified ingredient diets allows researchers to 
compare data from different studies, since the diet formulas are generally freely available to 
the public, while the “close source”, chow diets are differently formulated. Purified 
ingredients, on the other hand, are highly refined and contain just a single nutrient (ie. 
fructose). These ingredients have little variability and therefore provide consistency between 
batches, and so help to minimize data variability. There are numerous differences between 
chows and purified diets, creating countless variables, thus making it difficult to interpret 
the results when these diets are used together in a study. Chow is a nonpurified diet 
composed of a mixture of intact feed. In contrast, purified diets provide macronutrients as 
purified ingredients. For example, carbohydrate in chow diets is derived from complex 
mixtures of corn and wheat flakes, wheat middlings, ground corn, and dried whey. In 
addition to carbohydrate, these ingredients provide variable amounts of protein, fat, 
vitamins, minerals, and various phytochemicals and other (anti)nutrients. Some of these 
compounds, in particular the phytoestrogens, may act as endocrine disruptors that alter 
endocrine milieu and disease progression and so are usually unwanted variables. Finally, 
purified ingredient diet formulas can be easily modified so that researchers can intentionally 
and specifically change one ingredient at a time, allowing them to study the effects of large 
or small changes in the nutritional quantity and quality of the diet. Because of these 
advantages, most metabolic disease animal research uses and requires purified ingredient 
diets. In addition to purified and chow diets, some scientists used what is known as the 
cafeteria diet (CAF) to induce obesity. In this model, animals are allowed free access to 
standard chow and water while concurrently offered highly pleasant, energy dense, 
unhealthy human junk foods including cookies, candy, cheese, and processed meats ad 
libitum. These foods contain a substantial amount of salt, sugar, and fat and are meant to 
simulate the human “Western diet”. However, the nutritive and nonnutritive components of 
these foods are not well defined. In addition, the animal may choose a different selection of 
foods each day. In this section, I discuss how high diets influence the phenotypes of the 
obesity and/or MetS in translated animals. 
2.1. The mouse models 
The advantages of mouse models that made them suitable for translating human conditions 
include a well-known genome, relative ease of genetic manipulation, a short breeding span, 
access to physiological and invasive testing, short reproductive cycle, large litter size, much 
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lower cost and possibility of conducting longitudinal studies using larger numbers of 
animals, rapid development of atherosclerotic plaques, only partial resemblance to humans, 
very high levels of blood lipids, useful for noninvasive imaging and large experience.  
Normal mice have traditionally not been ideal models of cardiovascular disease research 
since they typically have very low levels of TC and LDL-C but high levels of HDL-C. This 
is in contrast to humans in whom the reverse is true because unlike humans and several 
other animals, mice do not possess plasma cholesteryl ester transfer protein (CETP) and, 
therefore, about 70% of the plasma TC is found in HDL particles. Mouse models have 
proved to be useful to study development and progression of atherosclerotic lesion, and 
several reviews have extensively discussed the different available models (see review 
[15]). The ability of mice to maintain their cholesterol profile even in the face of high-
cholesterol diets means that very little actual atherosclerosis develops [16]. As wild-type 
mice are resistant to lesion development, the current mouse models for atherosclerosis are 
based on genetic modifications of lipoprotein metabolism with additional dietary 
changes. In order to ‘force’ the atherosclerosis phenotype on normal mice, it is usually 
necessary to combine high concentrations of dietary cholesterol with 0.25%-0.5% cholic 
acid which promotes fat and cholesterol absorption from the intestine [17]. However, 
cholic acid can also promote liver inflammation, decrease bile acid production, and alter 
circulating TG and HDL-C, it may independently affect the development of 
atherosclerosis [15]. Atherosclerosis is a complex multifactorial disease with different 
etiologies that synergistically promote lesion development. High-fat diets (HFDs) are 
used to model obesity, dyslipidaemia, atherosclerosis, IR and MetS in rodents (see 
reviews [18,19]. High-fat diet (HFD) feeding in mice increased systolic blood pressure and 
induced endothelial dysfunction [20] and some kind of nephropathy [21]. Different types 
of HFDs have been used with fat fractions ranging between 20% and 60% energy as fat as 
either animal-derived fats, such as lard or beef tallow, or plant oils such as olive or 
coconut oil [22]. Long-term feeding of rats (60% of energy) and mice (35% fat wt/wt) with 
HFD increased body weight compared to standard chow-fed controls [23]. Although the 
increase in body weight was significant after as little as 2 weeks, the diet-induced 
phenotype became apparent after more than 4 weeks of HFD feeding [23]. Long-term 
feeding with both animal and plant fat-enriched diets eventually led to moderate 
hyperglycaemia and impaired glucose tolerance in most rat and mouse strains [24]. Lard, 
coconut oil and olive oil (42% of energy content) increased body weight, deposition of 
liver TGs, plasma TGs and FFAs concentrations and plasma insulin concentrations [22]. 
Lard, coconut oil and olive oil caused hepatic steatosis with no signs of inflammation and 
fibrosis [22]. Although HFD induces most of the symptoms of human MetS in rodents, it 
does not resemble the diet causing MetS and associated complications, as the human diet 
is more complex than a HFD. Other major components of modern diets are refined 
carbohydrates and fructose. The epidemiologic data has proved that a significant 
correlation in the prevalence of diabetes with fat, carbohydrate, corn syrup (source of 
fructose), and total energy intakes. The striking features of these studies are the fact that 
intake of corn syrup was positively associated with T2D, while protein and fat were not 
(see review [25]). Most studies have utilized mice as animal models to define the role of 
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carbohydrate enriched diets in formation of different aspects of MetS. The interested 
readers will have to go to the current literature in order to understand more fully the 
fidelity of mice for translation of similar conditions in humans. In this context, high-fat 
high-carbohydrate (HFHC) diet contains 55% fructose and 45% sucrose (wt/vol) in 
drinking water has been fed to nongenetically modified adult male C57Bl/6 mice for 16 
weeks led to obesity and nonalcoholic steatohepatitis (NASH) [26]. HFHC has been used 
to induce hyperglycemia, glucose intolerance, IR, increased fat pad weight and adipocyte 
hypertrophy and commonly HFHC-fed mouse models used to screen therapeutic effects 
of various drugs and diets against MetS and its comorbidities (e.g., [27]). Charlton and 
colleagues recently proposed an obese mouse model of NASH that induced by feeding 
fast food (high SFs, cholesterol, and fructose) diet [28]. C57BL/6J mouse is T2D model by 
simply feeding HFD to nonobese, nondiabetic C57BL/6J mouse strain. It is characterized 
by marked obesity, hyperinsulinaemia, IR and glucose intolerance [29]. Diets contribute to 
T2D in mouse identical to human, and a HFD and sucrose administration appears to 
speed up the development of the disease in mice. In this context, impaired insulin 
secretion and/or impaired insulin action also contribute to the diabetic phenotype for 
these mice [30]. However, the mouse models are observed to develop diabetes in relation 
to profound obesity and do not display the same islet pathology as humans with T2D [31]. 
A large number of investigations also have been carried out within recent years, 
concerning the therapeutic action of various (bio)pharmaceutical and nutraceutical 
compounds on mouse models of lipoprotein disorders (e.g., [32]).  
2.2. The rat models 
Rats, like humans, showed different vulnerability to diet-induced obesity. At first, an animal 
model of diet-induced obesity is one introduced by Levin and coworkers [33] and 
developed into a purified diet model [34]. In this model, Sprague-Dawley (SD) rats fed a 
purified moderately high-fat (MHF) diet exhibit a bimodal pattern in body weight gain 
similar to that observed in humans. Approximately half of the rats gain weight rapidly 
compared with chow-fed rats (obesity prone [OP] or diet-induced obese [DIO]), whereas the 
other half gain BW at a rate similar to or lower than that of the chow-fed animals (obesity 
resistant [OR] or diet-resistant [DR]) [34-36]. Most rodents tend to become obese on HFD 
and very high-fat diet (VHFD), but there can be variable responses in glucose tolerance, IR, 
TGs, and other parameters depending on the strain and gender, and source of dietary fat 
[22,37]. When outbred SD and Wistar rats were placed on HFD (32 or 45 kcal% fat), there 
was a wide distribution in body weight gain and a subset of animals became obese, whereas 
others remained as lean as the animals fed with a low-fat diet (LFD) have shown that the rat 
model of diet-induced obesity develops mild hypertension accompanied by vascular and 
renal changes similar to those observed in obese hypertensive humans [35,38]. The MHF 
diet that they used contains 32% kcal fat, a value similar to the average Western diet, as 
opposed to many other models that have very high levels of fat [38]. All rats fed the MHF 
diet did not become obese and their body weight displayed a bimodal distribution. The 
increased body weight reflects an increase in the adipose mass in the OP rats versus the 
chow-fed rats [38].  
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Elevation of plasma TGs and FFAs was commonly observed in patients with diabetic 
dyslipidemia or obesity [39]. Evidence showed that hyperglycemia and 
hypertriglyceridemia had direct effects on arterial wall and induced endothelial dysfunction 
[40]. The elevation of TGs and fasting plasma glucose was noted in HFD studies [41]. 
However, the levels of TGs and TC in high-fat fed DR rats were no more than chow-fed 
control rats. The HDL-cholesterol level decreases in hypercholesterolemic and MHF-fed rats 
[38]. The TGs content of plasma, LDL, and VLDL has been increased in OP rats fed MHF 
diet after 3 weeks [38]. As opposed to cholesterol content, this difference is even greater after 
10 weeks of the MHF diet therefore authors concluded that factors other than diet like 
reduced growth hormone secretion are also responsible for the high levels of TGs in OP rats 
[38,42]. The underlying mechanism is not known. Insight into the differences in endocrine 
and lipoprotein metabolism may provide further evidences. For example, Yang et al’s study 
showed that DR rats had higher levels of plasma peptide YY, a gut-derived anorexigen, than 
DIO and the control groups. This indicates that a difference in appetite control is responsible 
for the lower caloric intake and weight gain in DR rats [43]. One of the common features of 
obesity in humans is dyslipidemia which occurs in rat model of diet-induced obesity and is 
frequently associated with hypertension [38]. I have decided to ignore molecular 
mechanisms of hypertension in OP rat because of limited space. However, hypertension 
developed in OP, but not OR, rats, is a multifactorial disorder and diet is not the major 
factor that causes the high blood pressure in this model.  
According to Barker hypothesis, adult metabolic diseases are programmed during fetal life 
[44]. To investigate the mechanisms by which altered intrauterine milieu predisposes to later 
development of MetS, different animal models have been developed (see review [45]). 
Interestingly, offspring of rats fed high saturated fats during pregnancy have fetal IR [46], 
abnormal cholesterol metabolism [47] and raised adult blood pressure [48]. Furthermore, the 
outbred Sprague-Dawley DIO and DR rats have been selectively bred over time such that 
their future body weight response to a HFD is known in utero, allowing the researcher to 
look early in life (prior to the onset of obesity) for genetic traits that may later predispose 
them to their DIO or DR phenotypes [37,49]. 
The inbred obese Zucker diabetic fatty (ZDF) rat is high-fidelity model with close 
resemblance to human case in obesity and T2D. The males become obese and diabetic on a 
LFD, but HFD feeding promotes more robust disease. The female ZDF rat is unique in that 
while they are obese, they do not develop diabetes unless fed a diet (in this case, chow-
based) containing 48 kcal% fat [50]. The female ZDF rat is also suitable model mimics pre-
diabetic state in humans because she shows a prolonged period of insulin sensitivity prior to 
the onset of diet-induced diabetes [51]. The ZDF rats show profound dyslipoproteinaemia 
with increased TC and TGs levels and lower chylomicra disposal rates that mimics 
conditions occurred in human case of obesity [52]. Although normal rats are not ideal model 
of cardiovascular disease research since they typically have very low levels of TC and LDL-
C but high levels of HDL-C, they are mild diet-responsive. The ability of rats to sustain their 
cholesterol profile even in the face of high-cholesterol diets means that very little actual 
atherosclerosis develops [16]. However, feeding Wistar rats a high calorie "Western diet" 
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(45% fat) for up to 48 weeks induces obesity and cardiac dysfunction, while a high fat diet 
(60% fat) induces obesity only [53]. The "Western diet" composed of a purified ingredient 
SF-rich HFD, and cholesterol (~0.2% by weight) can elevate TC and LDL-C and in turn cause 
atherosclerosis in certain rodent models and humans [54]. A mixture of high levels of 
dietary cholesterol with 0.25%-0.5% cholic acid has been used to induce atherosclerosis 
phenotype on normal rats and mice for many years ago [55]. More recently, Zaragosa and 
colleagues introduced various animal models of cardiovascular diseases (see review [56]). 
Surprisingly rat does not develop atheroma in the process of atherosclerosis (see review 
[56]). Generally rats are highly resistant to the development of atherosclerosis because they 
lack physiological resemblance on many aspects with humans that are pathophysiologically 
important [57]. For example, HDL is dominating lipoprotein in these animals and rat 
platelets are generally resistant in hyperlipidemic condition (see review [58]). Rats are 
potentially practical model for studying hypercholesterolemia along with hypertension (see 
review [58]). They exhibit augmented thrombotic response and develop coronary 
atherosclerotic lesions under hypertensive and hyperlipidemic conditions (e.g., [59]). 
Triglyceride-rich diets containing various amounts of cholesterol, with or without cholic 
acid have been used to induce hypercholesterolemia in rats. The fat sources vary from lard 
to soybean, canola or sunflower oils. Nevertheless, the question of the caloric value of the 
employed diets has not yet been considered properly since their high fat content, which is 
the strategy used in order to induce hypercholesterolemia, leads to lower ingestion by the 
animals and induces malnutrition. To overcome this shortcoming, Matos and colleagues [60] 
proposed a diet containing 25% soybean oil, 1.0% cholesterol, 13% fiber (cellulose) and 
4,538.4 Kcal/Kg that led to an increase in LDL-C, a decrease in the HDL-C fraction and 
affected less the hepatic function of the rats during eight weeks. Roberts and colleagues 
presented a rat model of diet-induced syndrome X and they explored potential mechanisms 
of hypercholesterolemia in diet-induced syndrome X [61]. To induce syndrome X, female 
Fischer rats were fed a high-fat (primarily from lard plus a small amount of corn oil), 
refined-carbohydrate (sucrose) diet for 20 months [61]. Sampey and colleagues [62] have 
demonstrated that the CAF is a more robust model of MetS than lard-based HFD and that 
the rapid-onset of weight gain, obesity, multiorgan dysfunctions and pathologies observed 
in the CAF model more closely reflect the modern human condition of early onset obesity. 
However, they did not repot possible lipid-lipoprotein disorders that may be occurred in 
their model. Recently, Manting and colleagues [63] have shown that a combination of 
chronic stress and HFD (83.25% basal feed, 10% lard, 1.5% cholesterol, 0.2% sodium 
taurodeoxycholate, 5% sugar and 0.05% propylthiouracil) can induce lipid metabolism 
disorder in Wistar rats and they claimed that their multiple factor model better mimics the 
disease characteristics of human beings.  
2.3. The hamster models 
Hamsters are another animal model can be used to assess some aspects of MetS. Like rats 
and mice, HDL-C is predominant plasma cholesterol-rich lipoprotein in these animal, but in 
contrast, dietary cholesterol (~ 0.1%) can significantly elevate LDL-C and like humans, SF 
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can increase these levels further [64]. The combination of high dietary SF and cholesterol is 
commonly used to promote atherosclerosis in these animals and atherosclerotic lesions 
similar to those found in humans can be found after prolonged feeding periods [65]. 
Actually, cholesterol itself may not always be necessary for this phenotype, since a purified 
diet with no cholesterol but high concentrations of SF can promote more aortic cholesterol 
accumulation compared to a diet with both cocoa butter and 0.15% cholesterol [66]. 
Cholesterol-fed hamsters have been used to screen therapeutic anti-atherosclerotic and 
hypolipidemic properties of (phyto)medicines (e.g., [67,68]). Hamsters have been proposed 
as an animal model to evaluate diet-induced atherosclerosis since the 1980s [69]. Relative to 
other normal rodent models, hamsters have a low rate of endogenous cholesterol synthesis, 
cholesteryl ester transfer protein (CETP) activity and tissue specific editing of 
apolipoprotein (apo) B mRNA and secretion of apo B-100 from the liver and apo B-48 from 
the small intestine. Hamsters, like humans, take up approximately 80% of LDL-C via the 
LDL receptor pathway. The morphology of aortic foam cells and lesions in hamsters fed 
atherogenic diets was reported to be similar to human lesions [70]. Recently, in a systematic 
review Dillard and colleagues concluded that the Golden-Syrian hamster does not appear to 
be a constructive model to determine the mechanism(s) of diet-induced development of 
atherosclerotic lesions (see review [71]) however the authors only concentrated on 
atherogenecity of cholesterol- and fat-rich diets in hamster models of atherosclerosis.  
Leung and colleagues investigated intestinal lipoprotein production and the response to 
insulin sensitization in the high fat-fed Syrian Golden hamster for 5 weeks [72]. They 
concluded that Syrian Golden Hamsters were fed 60% fat is a good model of nutritionally-
induced IR that intestinal overproduction of lipoproteins appear to contribute to the 
hypertriglyceridemia of IR in this animal model and insulin sensitization with rosiglitazone 
(an insulin sensitizer) ameliorates intestinal apoB48 particle overproduction in this model. 
An appropriate dyslipidemic animal model that has diabetes would provide an important 
tool for research on the treatment of diabetic dyslipidemia. Ten days of high fat feeding in 
golden Syrian hamsters resulted in a significant increase in IR and baseline serum lipid 
levels accompanied by a prominent dyslipidemia. Thirteen days of treatment with 
fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR alpha) selective 
agonist, produced a dose-dependent improvement in serum lipid levels characterized by 
lowered VLDL-C and LDL-C and raised HDL-C in a fashion similar to that seen in man [73]. 
Various diet formula, fat resources and time tables have been found to induce some aspects 
of MetS in the literature. For example, a diet consisted of 80 g of anhydrous butterfat, 100 g 
of corn oil, 20 g of Menhaden fish oil and 1.5 g of cholesterol has been used to encourage 
hypercholesterolemia in male golden Syrian hamsters for 21 days [68]. Male golden 
hamsters were given 15% HFD contained 100 g of lard and 50 g of soybean oil and 100 g of 
sucrose showed diabetic dyslipidemia for eight weeks [74]. F1B hamster is a genetically-
defined hamster, derived from two highly inbred lines, namely by crossbreeding between 
Bio 87.20 female with a Bio 1.5 male. F1B hamster is an exciting animal model for 
hyperlipidemic-related applications. The F1B strain is very responsive to SF and cholesterol 
by increasing the non-HDL fraction to a greater extent than the HDL fraction [75]. Dietary 
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fatty acid chain length, degree of saturation and cis-trans conformation have been shown to 
alter several metabolic pathways involving cholesterol throughout the body, the combined 
effect of which is reflected in plasma lipid and lipoprotein profiles (see review [76]). 
Interestingly, intake of trans-fatty acids in shortenings and margarines has been linked to 
increased risk of cardiovascular disease through effects on lipoprotein metabolism and 
substituting trans-fatty acids for either saturated or polyunsaturated fatty acids results in 
more deleterious lipid-lipoprotein profiles [77]. Hamsters are candidate model to investigate 
cardiometabolic risks of different fat resource and fat-rich diets [78]. Similarity with the 
human LDL receptor gene, makes hamster ideal to study LDL receptor antagonists and also 
useful for drugs which interfere with CETP activities and reverse cholesterol transport 
(RCT) from peripheral tissues to the liver for biliary and fecal excretion [79]. A considerable 
amount of experimental attention is currently directed at understanding the in vivo 
mechanisms of RCT. Although not established in vivo, RCT is thought to be impaired in 
patients with MetS, in which liver steatosis prevalence is relatively high. In this sense, 
Briand and coworkers [80] introduced a hamster model of MetS to study RCT. These 
scientists with the help of HFT diet containing 27% fat, 0.5% cholesterol, and 0.25% 
deoxycholate as well as 10% fructose in drinking water for 4 weeks induced promoted IR, 
dyslipidemia with significantly higher plasma non-HDL-C concentrations and CETP 
activity, and hepatic steatosis. In vivo RCT was assessed by intraperitoneally injecting (3)H-
cholesterol labeled macrophages. Finally their results indicate a significant increase in 
macrophage-derived cholesterol fecal excretion, which may not compensate for the diet-
induced dyslipidemia and liver steatosis [80]. One of the main target organs of MetS is liver, 
in which it manifests itself as NAFLD [81]. Bhathena and colleagues currently developed a 
triumphant BioF1B Golden Syrian hamster model of MetS that successfully manifested 
hyperlipidemia, IR and NAFLD [81]. They induced this model by feeding hamsters a high-
fat, high-cholesterol, inadequate methionine- and choline-containing diet. In addition to F1B 
hamster strain from Biobreeders (Watertown, MA) that commonly used to study diet-
induced metabolic disorders other three outbred strains are Charles River (CR), Sasco and 
Harlan (see review [71]). All these strains are derived from inbred or outbred Golden-Syrian 
hamster.  
Similar to rats, hamsters fed high fructose diets (~60% of energy) may develop IR and 
hypertriglyceridemia in TG after only two weeks compared to diets low in fructose [72,73]. 
Interestingly, hamsters fed high-sucrose diets did not have elevated TG levels and 
developed only mild IR relative to those fed diets high in fructose [72]. Avramoglu and 
colleagues reviewed mechanisms of metabolic dyslipidemia in insulin resistant states (see 
review [82]). They developed an explanatory fructose-fed hamster model of insulin 
resistance to study hepatic lipid metabolism as its lipoprotein metabolism as described 
previously [83,84]. Hamsters exhibit obesity, hypertriglyceridemia, increase plasma FFAs 
concentration and IR if fed fructose-rich diet for a two week period. Fructose feeding 
induced a noteworthy increase in synthesis and secretion of total TGs as well as VLDL-TG 
by primary hamster hepatocytes [73]. The microsomal triglyceride transfer protein plays a 
pivotal role in VLDL assembly and its activity showed a striking 2.1-fold elevation in 
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hepatocytes derived from fructose-fed versus control hamsters [73]. The apoB production 
also has been increased in the fructose-fed hamsters [73]. Fructose-fed hamster also has been 
introduced as an exploratory animal model to excavate role of intestinal lipoprotein 
overproduction in the dyslipidemia of insulin-resistant states [74]. The authors have shown 
that fructose feeding for 3 weeks increases secretion of apoB48-containing lipoproteins in the 
fasting state and during steady state fat feeding. Wang and coworkers [75] investigated the 
composition of plasma lipoproteins in hamsters fed high-carbohydrate diets of varying 
complexity (60% carbohydrate as chow, cornstarch, or fructose) for 2 weeks. They showed 
that hamsters fed the high-fructose diet showed significantly increased VLDL–triglyceride 
(92.3%), free cholesterol (68.6%), and phospholipid (95%), whereas apolipoprotein B levels 
remained unchanged. Fructose feeding induced a 42.5% increase LDL–triglyceride 
concurrent with a 20% reduction in LDL–cholesteryl ester. Compositional changes were 
associated with reduced LDL diameter. In contrast, fructose feeding caused elevations in all 
HDL fractions.  
2.4. The guinea pig models  
A number of seminal reviews on the details of the criteria that make guinea pigs suitable 
animal models for studying lipoprotein metabolism are available (see reviews [85-87]) and a 
summary will be presented here. Guinea pigs in contrast to other rodents have higher levels 
of plasma LDL-C compared to HDL-C. As humans, guinea pigs have higher concentrations 
of free compared to esterified cholesterol found in the liver and they show evidence of 
moderate rates of hepatic cholesterol synthesis and catabolism. Similar to humans, the 
binding domain for the LDL receptor of guinea pigs discriminates normal and familial 
binding defective apo B-100 and apo B mRNA editing in liver is scarce (< 1%) compared to 
18 to 70% in other species [88]. The three important proteins involved in lipoprotein 
remodeling and RCT (CETP, lecithin:cholesterol acyltransferase (LCAT), and lipoprotein 
lipase (LPL) have been reported in guinea pigs.  
Guinea pigs have been used as models to dissect the mechanisms by which various dietary 
fat resources influences plasma lipid-lipoprotein profiles. In contrast to hamsters they do not 
possess a fore-stomach fermentation which modifies dietary macronutrients before reaching 
the small intestine [89]. Guinea pigs are not only superior models for studying the 
mechanisms by which statins [90], cholestyramine [91], apical sodium bile acid transport 
inhibitors [92] and microsomal transfer protein inhibitors [93] lower plasma LDL-C but also 
are selected to investigate the mechanisms by which certain drugs or toxins affect lipid-
lipoprotein metabolism (e.g.,[94]). Guinea pigs respond to dietary fat saturation, dietary 
cholesterol and dietary fiber by alterations in LDL-C (see review [87]). For example, the SF-
rich diet will increase TC and LDL-C levels much more than polyunsaturated fat (PF)-rich 
diet in guinea pigs and cholesterol-rich diets can further increase TC and LDL-C levels [95].  
The suitability of guinea pigs as models of atherosclerosis is augmented by an array of review 
and assessment features (see review [59]). However, guinea pigs do not develop advanced 
atherosclerotic lesions, and are not an entrenched model for atherosclerosis progression [96]. 
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High plasma level of lipoprotein (a) (also called Lp(a)) is associated with coronary heart 
disease and other forms of atherosclerosis in humans (see review [97]), and as primates, 
hedgehogs [98] and guinea pigs possess Lp(a) among normal animal models [99]. Guinea pigs 
are practical model to study the role of oxidized LDL (oxLDL) in progression of atherosclerosis 
[100]. Initial atherosclerosis induced by various formula of HFD in guinea-pigs. Intake of HFD 
(guinea-pig pellet diet + 0.2% w/w cholesterol) can induce the onset of early atherosclerotic 
changes in coronary artery, aorta and major organs at least for one month [101]. High SF diet 
supplemented with high cholesterol (0.25%) will advance an atherosclerotic process for twelve 
weeks in guinea pigs [102]. Yang and colleagues [103] introduced a hyperlipidemic guinea pig 
model in a comparative investigation. They concluded that different response of TG 
metabolism to a HFD (0.1% cholesterol and 10% lard) in guinea pigs and rats suggests that 
Hartley guinea pigs could be a better hypertriglyceridemia animal model than rats for research 
on lipid metabolism disorders and hypolipidemic drugs. It seems that chronic dyslipidemia 
associated with hypertriglyceridemia may reduce auditory function. In this context guinea 
pigs fed a HFD used as an animal model to find the relationship between of sensorineural 
hearing loss and dyslipidemia [104]. 
As rats, guinea pigs are accepted models for studying fetal programming of cardiovascular 
diseases. Interestingly, adipogenesis in the guinea pig is very active during early postnatal 
life and was altered by a maternal HFD; thus, it is an adequate model for intrauterine fat 
deposition [105]. More studies are requested to explore lipid-lipoprotein profiles of guinea 
pigs that received a maternal HFD. Caillier and colleagues [106] currently generated a 
guinea pig model of MetS by 150-day exposure to diabetogenic high fat high sucrose or the 
high fat high fructose diets. To my knowledge, it would be early to consider guinea pig as 
an animal model of MetS since the literatures are scarce. 
2.5. The rabbit models 
A century ago, rabbits were used as translated animal models of atherosclerosis [107]. Since 
then, a number of animal models have been used to explain the relationship between 
disorders of lipid metabolism and atherogenesis (see reviews [108,109]). In this sense, 
dietary lipid manipulation and use of naturally defective animals, such as Watanabe 
heritable hyperlipidemia (WHHL) rabbits, have been the focus of most experimental 
settings (see chapter 22). Rabbits are appropriate animal models for studying lipoprotein 
metabolism and its disorders because they share with humans several aspects of lipoprotein 
metabolism, such as similarities in composition of apolipoprotein B containing lipoproteins, 
hepatic production of apo B 100-containing VLDL, plasma CETP activity, human-like apo B, 
low hepatic lipase activity and high absorption rate of dietary cholesterol. Unlike humans, 
rabbits are hepatic lipase–deficient and do not have an analogue of human apo A-II. Rabbits 
do not form spontaneous atherosclerotic lesions and therefore require very high cholesterol 
levels to induce more advanced disease (see review [110]). Rabbits also have significant 
differences in their lipid metabolism from humans, which can result in their development of 
“cholesterol storage syndrome” while on high-cholesterol diets (0.5–3%), with cholesterol 
deposited in their liver, adrenal cortex, and reticuloendothelial and genitourinary systems 
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[108]. We found that a high-cholesterol diet contained in 0.47% cholesterol would be 
tolerable for adult male rabbits for 4 weeks but our high-cholesterol diet was mildly 
atherogenic [94,111]. The atherosclerotic lesions of rabbits do not completely resemble those 
in humans [108] and the formed lesions are more fatty and macrophage rich than human 
[112]. Atherogenic diets are usually associated with hypercholesterolemia and the 
development of atherosclerotic lesions in the aortic arch and thoracic aorta rather than in the 
abdominal aorta that is almost always affected in humans. New Zealand White rabbits are 
the strain commonly used in atherosclerosis research. Although they have low plasma TC 
concentrations and HDL as dominant lipoprotein [113], βVLDL becomes the major class of 
plasma lipoproteins when exposed to cholesterol-rich diet (see review [59]). In conjunction 
with chylomicron remnants, βVLDL becomes highly atherogenic. Long-term experiments 
using diets high in cholesterol are discouraging in rabbits, because they cannot increase the 
excretion of sterols and resulting hepatotoxicity does not allow the animal to survive (see 
review [114]).  
Various HFD and intervention period have been used to induce MetS in rabbits or its 
components like IR, visceral obesity, hypertension, dyslipidemia (e.g., [115,116]). Rabbits are 
suitable animals to investigate MetS-associated multiorgan dysfunctions. Helfenstein and 
colleagues recently proposed an experimental model of impaired glucose tolerance combined 
with hypercholesterolaemia induced by diets (high-fat/high-sucrose (10/40%) and cholesterol-
enriched diet for 24 weeks) that gained weight, increased blood glucose, TC, LDL-C, TGs, and 
decreased HDL-C in New Zealand male rabbits [117]. Their cheap model reproduced several 
metabolic characteristics of human DM and promoted early signs of retinopathy. Corona and 
colleagues [118] reviewed relationships between hypogonadism and MetS emphasizing their 
possible interaction in the pathogenesis of cardiovascular diseases. However they concluded 
that the clinical significance of the MetS-associated hypogonadism needs further clarifications. 
Vignozzi and colleagues [119] described an animal model of MetS obtained by feeding male 
rabbits for 12 weeks. In their experiment, HFD-animals develop hypogonadism and all the 
MetS features like hyperglycemia, glucose intolerance, dyslipidemia, hypertension, and 
visceral obesity. A recently established rabbit model of HFD-induced MetS showed 
hypogonadism and the presence of prostate gland alterations, including inflammation, 
hypoxia and fibrosis [120]. Rabbits fed a cholesterol-rich diet (1% cholesterol) for 8 weeks and 
12 weeks share several physiopathological aspects of NAFLD [121]. Because this model is not 
insulin resistant and obese, it may be useful for elucidating the mechanism of NAFLD related 
mainly to hyperlipidemia. 
3. Spontaneous animal models of lipoprotein disorders 
The pathophysiology of disorders of lipoprotein metabolism of humans cannot highly 
translated to wild-type rodents since they are very resistant to atherogenesis and have no 
similarity to human lipid and lipoprotein metabolism; further, they do not develop 
cardiovascular diseases identical to humans. Therefore search for more reliable model is still 
continuing. In this regard, pig, is a considered a very good model of human atherosclerosis, 
because it is similar to humans in terms of body size and other physiological features (see 
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review [122]). Pigs spontaneously develop atherosclerosis even on a normal porcine diet and 
dietary modification lead to sever atherosclerosis [123]. As humans, pigs transport most 
cholesterol in LDL-C and dietary modification alters their plasma lipoproteins closely 
resemble those occurring in humans. In contrast to rodents, swine atherosclerosis, like the 
human illness, progresses to advanced stages (see review [122]). For example, mini-pigs fed 
fat-enriched food showed fatty streaks in their abdominal and thoracic aorta and coronary 
arteries during 18 months [124]. Cholesterol contents of diets also affects the extension and 
exacerbation of atherosclerotic changes in pigs (see review [122]). Johansen and colleagues 
[125] suggested an obese Göttingen minipig model of MetS that was highly responsive to a 
high fat high energy diet. Several swine models of T2D and IR have been proposed (see 
review [18]). However, spontaneity in development of MetS and IR, is not common in this 
species [58]. Dogs do not naturally show atherosclerosis and cholesterol- and SF-rich diets 
combined with thyroid suppression is required for atherosclerosis development [126]. 
Beagles and miniature Schnauzer dogs show useful similarities with human in cholesterol 
synthesis, and lipoproteins level [127,128]. Feline DM, in both spontaneous and inducible 
forms, therefore provides a reliable animal model of human T2D and may provide 
additional insights into the clinical, physiological, and pathological features of this disease 
(see review [129]). Considerably more studies must be forthcoming to establish firmly how 
lipoprotein profile participates in pathogenesis of atherosclerosis, DM and possibly MetS in 
pet animal since companion animal obesity would be a serious veterinary medical concern 
in near future [130]. The subject of suitability of other domesticated animal species such as 
pigs and sheep, as well as feral, migrating and hibernating species for studying lipid and 
lipoprotein metabolism has been concisely reviewed (see review [131]). For thorough 
coverage of this aspect of animal models, this work is recommended.  
A number of other interesting wild rodents that are explanatory or exploratory animal 
models of different disorders of lipid and/or carbohydrate metabolism have been 
introduced. Recently, Octodon degus (degu) has been proposed as an animal model of diet-
induced development of atherosclerosis [132]. To induce atherosclerosis, degus were fed for 
16 weeks chow containing 0.25% cholesterol and 6% palm oil. Cholesterol-fed degus 
exhibited 4- to 5-fold increases in TC, principally in the VLDL-C and LDL-C fractions and 
developed cholesteryl ester-rich atherosclerotic lesions throughout the aorta [132]. 
Hedgehogs are homologous animal models for studying roles of Lp(a) in atherosclerosis 
[98]. Sand rat, Tuco-Tuco and spiny mouse are unusual models of diet-induced obesity and 
T2D (see review [12]. In laboratory condition, sand rat (Psammomys obesus) develops obesity 
and diabetes when fed on standard chow (high energy diet) instead of its usual energy-
diluted vegetable diet composed mainly of saltbush Atriplex [133]. Surprisingly, sand rats 
are studied extensively and serve as more statable polygenic model for the study of 
diabesity syndrome [133,134]. Spiny mouse (Acomys calirinus) is another small rodent living 
in semiarid areas of eastern Mediterranean. They gain weight and exhibit marked impaired 
pancreatic beta cell when they are placed in captivity on high energy rodent lab chow [135]. 
Ctenomis talarum (Tuco-tuco) is another feral species which exhibit similar characteristic 
features of sand rat and spiny mice when fed on high energy rodent diet [136]. Brandt's vole 
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(Lasiopodomys brandtii) is another rodent model used in diet-induced obesity [137]. The Nile 
grass rat (NGR), Arvicanthis niloticus, is a herbivorous rodent inhabiting dry savanna, 
woodlands, and grasslands in Africa. Noda and colleagues [138] recently showed that the 
NGR is a precious, spontaneous model for exploring the etiology and pathophysiology of 
MetS as well as its various complications.  
Avian models of human atherosclerosis include pigeon, chicken, Japanese quail, turkey and 
parrots. Although these avian models are not frequently used in studying atherosclerosis, it 
is worthy to note, that spontaneous atherosclerosis in the chicken was first described in 1914 
[139]. Use of pigeon models of atherosclerosis has been extensively reviewed (see review 
[140]). Briefly, the most important key points supporting the use of pigeons as models for 
human atherosclerosis include: 1. Pigeons are hypercholesterolemic compared to humans. 2. 
Pigeons are primarily HDL-C carriers but βVLDL-C and LDL-C become major lipid carriers 
when these animals are fed cholesterol-rich diet. 3. Their lipid metabolism and lesion 
progression are similar to humans. 4. Pigeons also resemble humans in cellular and vascular 
dysfunctions involving in atherogenesis. 5. Pigeons are negative animal models to study 
relevance of apoE, apo B48, chylomicra or LDL receptor in atherosclerosis pathology. 6. 
Pigeons are susceptible to both spontaneous and diet-induced atherosclerosis. Parrots are 
exceptional animal models to assess the impacts of various risk factors include elevated 
cholesterol level, diet composition, social stress and inactivity (similar to sedentary behavior 
in humans) on occurrence and progression of atherosclerosis (see review [59]).  
Phylogenetically, nonhuman primates are more similar to humans than other models in 
terms of lipid-lipoprotein profiles, pathophysiology of atherosclerosis, feeding habits, and 
genotype. It is demonstrated that, along with aging, some rhesus monkeys spontaneously 
develop diabesity (e.g. [141]). In this context, Macaca nigra is very valuable in studies focused 
on the interactions between atherosclerosis and diabetes [142]. Spontaneous diabetes has 
been documented in nonhuman primates include cynomolgus, rhesus, bonnet, Formosan 
rock, pig-tailed, celebes macaques, African green monkeys, and baboons (see reviews 
[18,143]). Diabetic nonhuman primates have detrimental changes in plasma lipid and 
lipoprotein concentrations and lipoprotein composition which may contribute to 
progression of atherosclerosis. As both the prediabetic condition (similar to MetS in 
humans) and overt diabetes become better translated in monkeys, their use in 
pharmacological studies is increasing. Monkeys can be categorized into hyperresponders 
and hyporesponders based on initiation, progression and severity of atherosclerotic lesions. 
Several nonhuman primates, such as squirrel monkeys, baboons, and wooly and spider 
monkeys, may develop spontaneous early stage (fatty streaks) atherosclerosis at different 
anatomical locations (see reviews [59,108]). Rare cases of LDL receptor deficiency in a rhesus 
monkey family associated with increased levels of LDL-C, Lp(a), and advanced 
atherosclerotic lesions in the aorta, and to a lesser extent in coronary arteries, were reported 
[144]. Nonhuman primates are more reliable model to study cardiovascular disease plus 
MetS rather than rodents, since they develop MetS and cardiovascular diseases as they age. 
They develop spontaneous (in some species) and high fat high cholesterol diet-induced 
atherosclerotic lesions [145]. Nonhuman primates are good model of hypertension and its 
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harmful effect on atherosclerosis development. The close similarity of plasma lipoprotein-
lipid level, plaque development and its calcification and mineralization with humans makes 
nonhuman primates practical model to explore the correlation between plasma lipids and 
plaque development (see review [59]). Kaufman and colleagues measured some 
anthropometric indices and metabolic parameters in 250 laboratory-born bonnet macaques 
living in social groups and maintained on commercial monkey chow [146]. Finally they 
concluded socially reared and housed bonnet macaques may provide a useful model for 
studying the pathogenesis, prevention, and treatment of the MetS. Recently, in an excellent 
investigation, Zhang and colleagues established a rhesus monkey model of spontaneous 
MetS using population screening approaches suitable to explore the pathogenesis of MetS in 
relation to cardiovascular disease and DM [147]. To sum, the inconsistency in anatomic 
location of atherosclerotic lesions, high cost of husbandry and veterinary services, limited 
animal availability, difficult handling, together with ethical queries are major obstacles in 
the use of monkeys as common animal models in studying MetS and its comorbidities.  
4. Conclusion 
The incidence of metabolic syndrome is increasing on a pandemic level. One of the major 
underlying cause and/or outcome of metabolic syndrome is dyslipidemia, which contribute 
greatly to the cardiovascular problems associated with the syndrome. The animal models 
have a vital role to play in extending our understanding of metabolic syndrome and its 
related comorbidities. Conventional laboratory animals such as mice, rats, hamsters, guinea 
pigs and rabbits have been examined to gain a better perceptive of the relationship between 
disorders of lipid metabolism and their clinical correlations. High-fat diets frequently used 
to induce different aspects of metabolic syndrome in rodent models. However, 
nonconventional animal models like pig, pigeon, and feral animals (e.g., spiny mice, sand 
rat, hedgehogs) can consider as spontaneous animal models suitable for studying both the 
pathogenesis and potential therapeutic agents in lipoprotein disorders. The attempts to find 
animal models relevant to the study of metabolic syndrome are continuing. 
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